Molecular subtype is determinant on inflammatory status and immunological profile from invasive breast cancer patients

Cancer Immunology, Immunotherapy

Volumn 61, Issue 11, 2012, Pages 2193-2201

  Herrera, A C S A ^a   Panis, C ^a   Victorino, V J ^a   Campos, F C ^a   Colado Simao A N ^a   Cecchini, A L ^a   Cecchini, R ^a  

^a STATE UNIVERSITY OF LONDRINA   (Brazil)

Author keywords

Breast cancer; Molecular subtypes; Oxidative stress; TGF ; TNF a

Indexed keywords

CANCER GROWTH FACTOR; CARBONYL DERIVATIVE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ESTROGEN RECEPTOR; GAMMA UROGASTRONE; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 12; MALONALDEHYDE; NITRIC OXIDE; PACLITAXEL; PROGESTERONE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; BREAST CANCER; CANCER GRADING; CANCER INFILTRATION; CANCER INVASION; CANCER PATIENT; CANCER STAGING; COMORBIDITY; CONTROLLED STUDY; FEMALE; HIGH THROUGHPUT SCREENING; HUMAN; IMMUNOMODULATION; IMMUNOREACTIVITY; INFLAMMATION; LIPID PEROXIDATION; MAJOR CLINICAL STUDY; OXIDATIVE STRESS; PRIORITY JOURNAL; TRIPLE NEGATIVE BREAST CANCER;

ADULT; ANTINEOPLASTIC AGENTS; ANTIOXIDANTS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CYTOKINES; DOXORUBICIN; FEMALE; HUMANS; INFLAMMATION; LIPID PEROXIDATION; MALONDIALDEHYDE; MIDDLE AGED; NEOPLASM INVASIVENESS; NITRIC OXIDE; OXIDATIVE STRESS; PACLITAXEL; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84870989699     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-012-1283-8     Document Type: Article

References (38)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. Cancer J Clin 61:69-90
2. Pourzand A, Fakhree BA, Hashemzadeh S, Halimi M, Daryani A (2011) Hormone receptor status in breast cancer and its relation to age and other prognostic factors. Breast Cancer Basic Clin Res 5:87-92
3. Su Y, Zheng Y, Zheng W, Gu K, Chen Z, Li G, Cai Q, Lu W, Shu XO (2011) Distinct distribution and prognostic significance of molecular subtypes of breast cancer in Chinese women: a population-based cohort study. BMC Cancer 11:292-303
4. Levano KS, Jung EH, Kenny PA (2011) Breast cancer subtypes express distinct receptor repertoires for tumor-associated macrophage derived cytokines. Biochem Biophys Res Commun 411(1):107-110
5. Voduc KD, Cheang MCU, Tyldesley S, Gelman K, Nielsen TO, Kennecke H (2010) Breast cancer subtypes and the risk of local and regional relapse. J Clin Oncol 28:1684-1691
6. Schnit SJ (2010) Classification and prognosis of invasive breast cancer: from morphology to molecular taxonomy. Mod Pathol 23:S60-S64
7. Halliwell B (2007) Oxidative stress and cancer: have we moved forward? Biochem J 401:1-11
8. Panis C, Victorino VJ, Herrera ACSA, Freitas LF, deRossi T, Campos FC, Colado Simǎo NA, Barbosa DS, Pinge-Filho P, Cecchini R, Cecchini AL (2011) Differential oxidative status and immune characterization of the early and advanced stages of human breast cancer. Breast Cancer Res Treat. doi: 10.1007/s10549-011-1851-1
9. Panis C, Herrera AC, Victorino VJ, Campos FC, Freitas LF, De Rossi T, Colado Simǎo AN, Cecchini AL, Cecchini R (2011) Oxidative stress and hematological profiles of advanced breast cancer patients subjected to paclitaxel or doxorubicin chemotherapy. Breast Cancer Res Treat. doi:10.1007/s10549-011-1693-x
10. Panis C, Lemos LGT, Victorino VJ, Herrera ACSA, Campos FC, Colado Simǎo NA, Pinge-Filho P, Cecchini AL, Cecchini R (2011) Immunological effects of Taxol and Adryamicin in breast cancer patients. Cancer Immunol Immunother. doi:10.1007/ s00262-011-1117-0
11. Kobiela J, Stefaniak T, Krajewski J, Kalinska-Blach B, Zurawa-Janicka D, Lachinski A, Gackowski D, Olinski R, Nowak J, Knap N, Lipinska B, Sledzinski Z, Wozniak M (2007) Dynamics of estrogen-induced oxidative stress. Acta Biochim Pol 54:289-295
12. Yau C, Benz CC (2008) Genes responsive to both oxidant stress and loss of estrogen receptor function identify a poor prognosis group of estrogen receptor positive primary breast cancers. Breast Cancer Res 10:R61
13. Tesarova P, Kalousova M, Trnková B, Soukupová J, Argalasová S, Mestek O, Petruzelka L, Zima T (2007) Carbonyl and oxidative stress in patients with breast cancer -is there a relation to stage of disease? Neoplasma 54:219-224
14. Repetto M, Reides C, Carretero MLG, Costa M, Griemberg G, Llesuy S (1996) Oxidative stress in blood of HIV infected patients. Clin Chim Acta 225:107-117
15. Gonzales-Flecha B, Llesuy S, Boveris A (1991) Hydroperoxideinitiated chemiluminescence: an assay for oxidative stress in biopsies of heart, liver and muscle. Free Radic Biol Med 10:93-100
16. Panis C, Mazzuco TL, Costa CZF, Victorino VJ, Tatakihara VLH, Yamauchi LM, Yamada-Ogatta SF, Cecchini R, Pinge-Filho P (2011) Trypanosoma cruzi: effect of the absence of 5-lipoxygenase (5-LO)-derived leukotrienes on levels of cytokines, nitric oxide and iNOS expression in cardiac tissue in the acute phase of infection in mice. Exp Parasitol 127:58-65
17. Reznick AZ, Packer L (1994) Oxidative damage to proteins: spectrophotometric method for carbonyl assay. Methods Enzymol 233:357-363
18. Miller GL (1959) Protein determination for large numbers of samples. Anal Chem 31:964
19. Arvold ND, Taghian AG, Niemierko A, Abi Raad RF, Sreedhara M, Nguyen PL, Bellon JR, Wong JS, Smith BL, Harris JR (2011) Age, breast cancer subtype approximation, and local reccurrence after breas-conserving therapy. J Clin Oncol. doi:10.1200/JCO. 2011.36.1105
20. Theriault RL, Litton JK, Mittendorf EA, Chen H, Meric-Bernstam F, Chavez-Macgregor M, Morrow PK, Woodward WA, Sahin A, Horotbagyi GN, Gonzalez-Angulo AM (2011) Age and survival estimates in patients who have node-negative T1ab breast cancer by breast cancer subtype. Clin Breast. doi:10.1016/ j.clbc.2011.05.002
21. Vestjens JH, de Boer M, van Diest PJ, van Deurzen CH, van Dijck JA, Boro GF, Adang EM, Bult P, Tjan-Heijnen VC (2011) Prognostic impact of isolated tumor cells in breast cancer axillary nodes: single tumor cell(s) versus tumor cell cluster(s) and microanatomic location. Breast Cancer Res Treat. doi:10.1007/ s10549-011-1771-0
22. Hernández-Aya LF, Chavez-MacGregor M, Le X, Meric-Bernstam F, Buchholz TA, Hsu L, Sahin AA, Do KA, Valero V, Hortobagyi GN, Gonzalez-Angulo AM (2011) Nodal status and clinical outcomes in a large cohort of patients with triple negative breast cancer. J Clin Oncol 29:2628-2634
23. Rahka EA, Reis-Filho JS, Baehner F, Dabbs DJ, Decker T, Eusebi V, Fox SB, Ichihara S, Jacquemier J, Lakhani SR, Palacios J, Richardson AL, Schnitt SJ, Schnitt FC, Tan PH, Tse GM, Badve S, Ellis IO (2010) Breast cancer prognostic classification in the molecular era: the role of histological grade. Breast Cancer Res 12:207
24. Dong SW, Wang W, Sui J, Deng XY, Chen XD, Zhang ZW, Liu X, Zhang JH, Yang QS, Jia YF, Song X (2011) Expression patterns of ER, HER2 and NM23-H1 in breast cancer patients with different menopausal status: correlation with metastasis. Mol Diagn Ther 15:311-319
25. Reyal F, Rouzier R, Depont-Hazelzet B, Bolet MA, Pierga JY, Alran S, Salmon RJ, Fourchotte V, Vincent-Salomon A, Sastre-Garau X, Antoine M, Uzan S, Sigal-Zafrani B, de Rycke Y (2011) The molecular subtype classification is determinant of sentinel node positivity in early breast carcinoma. PLoS ONE 6:e20297
26. Tanizaki J, Okamoto I, Sakai K, Nakagawa K (2011) Differential roles of trans-phosphorylated EGRF, HER2, HER3, and RET as hetrodimerisation partners of MET in lung cancer with MET amplification. Br J Cancer 105:807-813
27. Leek RD, Landers R, Fox SB, Ng F, Harris AL, Lewis CE (1998) Association of tumor necrosis factor alpha and its receptors with thymidine phosphorylase expression in invasive breast carcinoma. Br J Cancer 77(12):2246-2251
28. Xian LW, Li TP, Wei YE, Wu SP, Ma L (2011) Relation of advanced oxidation proteins products with VEGF and TGF-b1 in colon cancer cells exposed to intermittent hypoxia. Nan fang Ye Ke Da Xue Xue Bao 4:619-623
29. Okoh V, Deoraj A, Roy D (2011) Estrogen-induced reactive oxygen species-mediated signalings contribute to breast cancer. Biochim Biophys Acta 1815:115-133
30. Bhatnagar S, Panguluri SK, Gupta SK, Dahiya S, Lundy RF, Kumar A (2010) Tumor necrosis factor alpha regulates distinct molecular pathways and gene networks in cultured skeletal muscle cells. PLoS ONE 5(10):e13262
31. Lin S, Yang J, Elkahloun AG, Bandyopadhyay A, Wang L, Cornell JE, Yeh IT, Agyin J, Tomlinson G, Sun LZ (2012) Attenuation of TGF-b signaling suppresses premature senescence in a p21-dependent manner and promotes oncogenic Ras-mediated metastatic transformation in human mammary epithelial cells. Mol Cell Biol. doi:10.1091/mbc.E11-10-0849
32. Wang SE (2011) The functional crosstalk between HER2 tyrosine kinase and TGF-b signaling in breast cancer malignancy. J Signal Transduct. doi:10.1155/2011/804236
33. Czerniecki BJ, Koski GK, Koldovsky U, Xu S, Cohen PA, Mick R, Nisenbaum H, Pasha T, Xu M, Fox KR, Weisntein S, Orel SG, Vondeheide R, Coukos G, DeMichele A, Araujo L, Spitz FR, Rosen M, Levine BL, June C, Zhang PJ (2007) Targeting HER-2/ neu in early breast cancer development using dendritic cells with staged interleukin-12 burst secretion. Cancer Res 67(4):1842-1852
34. Xu L, Yin S, Banerjee S, Sarkar F, Reddy KB (2011) Enhanced anticancer effect of the combination of cisplatin and TRAIL in triple negative breast tumor cells. Mol Cancer Ther 10(3):550-557
35. Rahman M, Davis SR, Pumphrey JG, Bao J, Nau MM, Meltzer PS, Lipkowitz S (2009) TRAIL induces apoptosis in triple negative breast cancer cells with a mesenchymal phenotype. Breast Cancer Res Treat 113(2):217-230
36. Rahman M, Pumphrey JG, Lipkowitz S (2009) The TRAIL to targeted therapy of breast cancer. Adv Cancer Res 103:43-73
37. Wink DA, Vodovotz Y, Laval J, Laval F, Dewhirst M, Mitchell JB (1998) The multifaceted roles of nitric oxide in cancer. Carcinogenesis 19:711-721
38. Glynn SA, Boersma BJ, Dorsey TH, Yi M, Yfantis HG, Ridnour LA, Martin DN, Switzer CH, Hidson RS, Wink DA, Lee DH, Stephens RM, Ambs S (2010) Increased NOS2 predicts poor survival in estrogen receptor-negative breast cancer patients. J Clin Invest 120:3843-3854